BWM
VTGN icon

Bulltick Wealth Management’s VistaGen Therapeutics VTGN Stock Holding History

Bulltick Wealth Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7,445
Closed -$436K – 166
2021
Q4 		$436K Buy
7,445
+4,450
+149% +$290K 0.09% 90
2021
Q3 		$246K Buy
+2,995
New +$260K 0.06% 117

Other funds holding VTGN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return

Bulltick Wealth Management's VTGN Position: Q1 2022 in Review

Bulltick Wealth Management sold out of VistaGen Therapeutics (VTGN) in Q1 2022, closing a stake of 7,445 shares — an estimated $436K sold.

Bulltick Wealth Management first reported a position in VTGN in Q3 2021 and held it in 2 quarters. The position peaked at $436K in Q4 2021. 116 funds tracked by Wall St. Rank hold VTGN as of Q1 2022.

  • Bulltick Wealth Management reported no remaining VistaGen Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Bulltick Wealth Management sold 7,445 VistaGen Therapeutics shares in Q1 2022, an estimated $436K.
  • Bulltick Wealth Management first reported a position in VistaGen Therapeutics in Q3 2021 and held it in 2 quarters.
  • Bulltick Wealth Management's VistaGen Therapeutics position peaked at $436K in Q4 2021.
  • 116 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2022.

Based on Bulltick Wealth Management's 13F filing for Q1 2022, filed 25 Apr 2024.